Senzime AB logo

Senzime AB (SEZI)

Market Closed
5 Aug, 15:25
XSTO XSTO
kr
3. 98
+0.33
+9.0411%
kr
606.85M Market Cap
- P/E Ratio
- Div Yield
1.01M Volume
-1.23 Eps
kr 3.65
Previous Close
Add Transaction
Day Range
3.63 4.1
Year Range
3.85 7.38
Want to track SEZI and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

SEZI closed yesterday higher at kr3.98, an increase of 9.0411% from Tuesday's close, completing a monthly decrease of -13.4783% or -kr0.62. Over the past 12 months, SEZI stock lost -24.7637%.
SEZI is not paying dividends to its shareholders.
The last earnings report, released on Apr 22, 2026, exceeded the consensus estimates by 0.1%. On average, the company has fell short of earnings expectations by -0.1117%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on XSTO (SEK).

SEZI Chart

People also search for

Pricer AB
kr -
-
BioArctic AB
kr -
-
DIAMYD MEDICAL AB
kr -
-
Bactiguard Holding AB
kr -
-
Genovis AB
kr 19.78
+2.2751%

Senzime AB (SEZI) FAQ

What is the stock price today?

The current price is kr3.98.

On which exchange is it traded?

Senzime AB is listed on XSTO.

What is its stock symbol?

The ticker symbol is SEZI.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 606.85M.

Has Senzime AB ever had a stock split?

No, there has never been a stock split.

Senzime AB Profile

Health Care Technology Industry
Healthcare Sector
Mr. Philip Siberg CEO
XSTO Exchange
SE0002478776 ISIN
SE Country
59 Employees
- Last Dividend
16 Feb 2023 Last Split
- IPO Date

Overview

Senzime AB (publ) stands out as an innovative medical device company with a strong focus on developing, manufacturing, and marketing advanced patient monitoring systems. The company’s reach extends across Europe and the United States, serving the medical community by offering cutting-edge solutions aimed at enhancing patient care. Established in 1999 and based in Uppsala, Sweden, Senzime AB has carved a niche in the medical device industry through its robust product lineup, including the renowned TetraGraph system. A notable aspect of Senzime AB’s strategic operations includes a licensing and connectivity agreement with Masimo, underlining its commitment to integrate and streamline patient monitoring technologies with existing healthcare infrastructures.

Products and Services

  • TetraGraph - A quantitative neuromuscular transmission monitor designed to assess muscle function and neuromuscular block, providing real-time, precise data crucial for patient assessment during and after surgery.
  • TetraSens - Sensors specifically developed to measure muscle response to stimuli, thereby complementing the TetraGraph system's accuracy and reliability in neuromuscular monitoring.
  • TetraSens Pediatric - A specialized version of TetraSens designed for pediatric patients, offering tailored decision support for this sensitive demographic.
  • TetraConnect - A data management portal that facilitates the access, viewing, and exportation of data records from the TetraGraph monitor in various formats such as PDF and Excel, enhancing the efficiency of patient data management.
  • TetraGraph Device Connectivity - A feature that enables seamless data transfer from the TetraGraph Monitor to patient monitoring systems, thus integrating neuromuscular monitoring data into broader patient care protocols.
  • ExSpiron 2Xi - A non-invasive respiratory volume monitor that offers continuous, real-time monitoring of patients' respiratory status, aiding in the detection and prevention of respiratory complications.
  • TetraGraph Philips Interface - An interface that facilitates the transmission of neuromuscular monitoring parameters from the TetraGraph system to Philips patient monitors, integrating essential monitoring data into a centralised system for enhanced patient oversight.
  • CliniSenz Analyzer - Targets the need for postoperative and continuous patient monitoring in hospital settings, offering a sophisticated solution for real-time patient status assessment.
  • OnZurf Probe - A sterile single-use product leveraging micro-dialysis technology for continuous sampling from gastrointestinal organs, such as the esophagus, stomach, and liver, providing valuable insights into the patient’s internal chemistry and organ function.
  • TetraGraph Smart Cable Module - A collaboration between Senzime AB and Masimo resulting in a module that connects directly to Masimo's Root monitoring system and digital hubs. This innovation facilitates the integration of TetraGraph data with hospital clinical information systems or electronic health records, streamlining the workflow and enhancing patient care efficiency.

Contact Information

Address: Verkstadsgatan 8, Uppsala, Sweden, 753 23
Phone: 46 18 51 56 40